P Husis Therapeutics
Biotechnology, 3210 Merryfield Row, San Diego, California, 92121, United States, 1-10 Employees
Phone Number: 71********
Who is PHUSIS THERAPEUTICS
PHusis is designing precision medicines using its proprietary computational modeling platform, PHuDock to rapidly identify inhibitors of proteins with regulatory PH-domains that drive can...
Read More
-
Headquarters: 3210 Merryfield Row, San Diego, California, 92121, United States
-
Date Founded: 2009
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from PHUSIS THERAPEUTICS
Email
Phone
Similar Companies to PHusis Therapeutics
Ensysce Biosciences
-
11-50
-
$ 1 Million to 5 Million
Orphagen Pharmaceuticals
-
1-10
-
$ 5 Million to 10 Million
Polaris Pharmaceuticals
-
11-50
-
$ 1 Billion and Over
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding PHusis Therapeutics
Answer: PHusis Therapeutics's headquarters are located at 3210 Merryfield Row, San Diego, California, 92121, United States
Answer: PHusis Therapeutics's phone number is 71********
Answer: PHusis Therapeutics's official website is https://phusistherapeutics.com
Answer: PHusis Therapeutics's revenue is Under $1 Million
Answer: PHusis Therapeutics's SIC: 2836
Answer: PHusis Therapeutics's NAICS: 541714
Answer: PHusis Therapeutics has 1-10 employees
Answer: PHusis Therapeutics is in Biotechnology
Answer: PHusis Therapeutics top competitors include: Ensysce Biosciences , Orphagen Pharmaceuticals , Polaris Pharmaceuticals
Answer: PHusis Therapeutics contact info: Phone number: 71******** Website: https://phusistherapeutics.com
Answer: PHusis is designing precision medicines using its proprietary computational modeling platform, PHuDock to rapidly identify inhibitors of proteins with regulatory PH-domains that drive cancer growth. The approach provides PHusis with the means of identifying drug leads more rapidly and in a cost-effective manner. The result is, PHusis has built a pipeline of drug leads against some novel and critical cancer targets including PDK1, mutant KRAS and NRAS. Patients can be selected for treatment based on their mutational profile, eliminating unnecessary treatment of patients without the targets
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month